Clinical Trials Sponsored by Calimmune, Inc

Total 35399 results

Calimmune, Inc.

Completed

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Human Immunodeficiency Virus

United States
Calimmune, Inc.

Active, not recruiting

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

HIV-1 Infection | Receipt of Cal-1 Modified Hematopoietic Cellular Products

United States
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Altimmune, Inc.

Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Altimmune, Inc.

Active, not recruiting

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Spain, United Kingdom, Canada, United States, Germany
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Terminated

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Coronavirus Infection

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Healthy Volunteers

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

Study of the Safety and Immunogenicity of NasoVAX Extension

Influenza

United States
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Altimmune, Inc.

Unknown

NasoShield Study of Safety and Immunogenicity (NasoShield)

Healthy Volunteers

United States
Aimmune Therapeutics, Inc.

Completed

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

Peanut Allergy

United States, United Kingdom, France, Germany
Aimmune Therapeutics, Inc.

Completed

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PALISADE)

Peanut Allergy

United States, Spain, Ireland, Netherlands, Canada, United Kingdom, Germany, Denmark, Italy, Sweden
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Completed

ARTEMIS Peanut Allergy In Children (ARTEMIS)

Peanut Allergy

United Kingdom, Italy, France, Germany, Ireland, Spain, Sweden
Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Afimmune

Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)

Type 2 Diabetes | Hypertriglyceridemia

Georgia, United States, Germany, Israel, Latvia, Switzerland
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

Non Alcoholic Fatty Liver Disease

Georgia, Ukraine, United Kingdom
CoImmune

Terminated

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Altimmune, Inc.
Optimal Health Research

Completed

Immune Response Following Seasonal Influenza Vaccination

Influenza

United States
Afimmune

Recruiting

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Afimmune

Terminated

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Severe Acute Decompensated Alcoholic Hepatitis

United States, Georgia
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

COVID-19

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Influenza
Adimmune Corporation

Completed

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Albimmune SL

Not yet recruiting

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure. (ALBUMIM)

Septic Shock
Agalimmune Ltd.

Completed

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Superficial, Palpable, Unresectable/Metastatic Solid Tumour

United States, Israel, United Kingdom
NatImmune A/S

Unknown

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Cutaneous Warts

Denmark
Adimmune Corporation

Completed

Dose-finding Study for AdimrSC-2f Vaccine

COVID-19

Indonesia
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza

3

Subscribe